Haemonetics
293 hedge funds and large institutions have $4.52B invested in Haemonetics in 2018 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 90 increasing their positions, 105 reducing their positions, and 34 closing their positions.
100% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 34
17% more capital invested
Capital invested by funds: $3.87B → $4.52B (+$651M)
12% more funds holding
Funds holding: 261 → 293 (+32)
2.38% less ownership
Funds ownership: 98.85% → 96.47% (-2.4%)
14% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 105
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
92% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $15.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$105M |
| 2 |
Renaissance Technologies
New York
|
+$54.9M |
| 3 |
Man Group
London,
United Kingdom
|
+$40.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$34.6M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$100M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.1M |
| 3 |
Millennium Management
New York
|
-$80.5M |
| 4 |
BlackRock
New York
|
-$77.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$70.2M |
HAE Hedge Fund Activity: Q2 2018 in Review
293 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2018, worth a combined $4.52B — up 17% from $3.87B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new HAE positions and 34 closed out — a net gain of 34 holders — while 90 added to existing stakes and 105 trimmed.
The largest buyer was Jackson Square Partners, opening a new position worth an estimated $105M. The largest seller was Victory Capital Management, cutting an estimated $100M.
- 293 institutional investors held Haemonetics (HAE) as of Q2 2018, up from 261 in Q1 2018.
- Funds reported $4.52B of Haemonetics stock for Q2 2018, up 17% quarter-over-quarter.
- 68 funds opened new Haemonetics positions in Q2 2018 and 34 closed out, a net change of +34 holders.
- The largest Haemonetics buyer in Q2 2018 was Jackson Square Partners, an estimated $105M added.
- The largest Haemonetics seller in Q2 2018 was Victory Capital Management, an estimated $100M sold.
Based on aggregated 13F filings for Q2 2018.